Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > This is much more than "commenced"
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(128)
•••
Comment by MrMugsyon Jun 28, 2021 9:52am
148 Views
Post# 33459154

RE:RE:This is much more than "commenced"

RE:RE:This is much more than "commenced"
GameChangerBet wrote: Perhaps they're close to a deal and want to partner up for the start of Phase 3.
Could be a reason for the start to be slightly pushed out, buy some more time to finalize a deal.
Just speculating between the lines..

Actuarial wrote: "we’re now entering confidential discussions for the large markets"




Yes - I'm sure they would like to conclude an agreement.
All depends how many companies are in the running and how far the valuations are from ATE's expected payout.

I think you could very quickly get there if two sides can agree to a valuation based on milestone payments, up to and including a successful P3 (where P3 will still be run to Antibe's gameplan).

A deal could happen at anytime or at no time in 2021.  Sure, the odds are more likely for 2022 but we just don't know.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities